Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
20 participants
OBSERVATIONAL
2025-11-30
2028-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Anti-3-[18F]FACBC Imaging of Parathyroid Adenomas
NCT01574287
A Phase 1 Study of [225Ac]-FPI-1434 Injection
NCT03746431
Fractionated Stereotactic Radiotherapy in Patients With Acromegaly
NCT00934271
A Trial to Assess the Safety and Effectiveness of Lutetium-177 Octreotate Therapy in Neuroendocrine Tumours
NCT01876771
Spanish Series of Patients Treated With the Radionuclide Lutetium177
NCT04949282
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The investigators aim to describe the uptake pattern of rubidium-82 chloride in parathyroid adenomas as well as compare the uptake pattern of rubidium-82 chloride to that of 18F-fluorocholine in patients with parathyroid adenoma.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
PET/CT imaging with rubidium-82
PET imaging of the neck will be started immediately before infusion of 10 Megabecquerels per kilograms of rubidum-82 over 30 seconds. The acquisition will last 10 minutes. This will be followed by a non-contrast low-dose CT of the neck for localization and attenuation correction.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Ability to undergo imaging logistics
3. Ability to provide informed consent
4. Biochemical evidence of primary hyperparathyroidism
5. Documented parathyroid adenoma on prior 18F-fluorocholine imaging
Exclusion Criteria
2. Breastfeeding or pregnancy
3. Claustrophobia or inability to undergo imaging logistics
4. Any other history, condition, therapy, or uncontrolled intercurrent illness, which could in the opinion of the investigator affect compliance with study requirements or which would make the participant unsuitable for this study
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Matthieu Pelletier-Galarneau, MD MSc
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Matthieu Pelletier-Galarneau, MD MSc
Chief of the Nuclear Medicine Department
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Montreal Heart Institute
Montreal, Quebec, Canada
Montreal Jewish General Hospital
Montreal, Quebec, Canada
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Pelletier-Galarneau
Role: CONTACT
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MP-33-2025-3547
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.